EU pharmaceuticals inquiry – where will the commission come knocking?
This article was originally published in Scrip
TheEuropean Commission's preliminary report on competition in the pharmaceutical sector has certainly generated a buzz in the industry. Now the dust has settled, what conclusions can be drawn from the facts and figures in this controversial 400-page document? Can more companies expect a knock on the door from the commission's inspectors?